Ptc Therapeutics Patent-Cliff Exposure & CMS Drug Spending Portfolio

Ptc Therapeutics (US): 2 reconciled FDA prescription therapies (100.0% 2025 to 2030 cliff risk), $218.1M 2024 CMS Part D & Medicaid spend, and 10 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies2
2025 to 2030 Patent-Cliff Revenue Exposure100.0%
Primary Portfolio LOE Date2026-01-01
2024 CMS Total Public Spend$218.1M
2024 Medicare Part D Spend$15.4M
2024 Medicaid Spend$202.7M
California HCAI SB 17 Filings10 WAC filings (max 76.6% 2-yr change)